Pricey or priceless: cost-effectiveness of respiratory syncytial virus (RSV) prevention in infants

被引：1
|
作者：
Li, Xiao [1 ]
Bilcke, Joke [1 ]
Beutels, Philippe [1 ]
机构：
[1] Univ Antwerp, Ctr Hlth Econ Res & Modelling Infect Dis CHERMID, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium
来源：
LANCET REGIONAL HEALTH-AMERICAS | 2024年 / 29卷
关键词：
D O I：
10.1016/j.lana.2023.100657
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
  • [22] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [23] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [24] Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey
    Oncel, Mehmet Yekta
    Mutlu, Banu
    Kavurt, Sumru
    Bas, Ahmet Yagmur
    Demirel, Nihal
    Akyol, Mesut
    Erdeve, Omer
    Dilmen, Ugur
    TURKISH JOURNAL OF PEDIATRICS, 2012, 54 (04) : 344 - 351
  • [25] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
    Neovius, Kristian
    Buesch, Katharina
    Sandstrom, Kristina
    Neovius, Martin
    ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
  • [26] Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study
    Do, Lien Anh Ha
    Le, Nguyen Thanh Nhan
    Mahmud, Sarwat
    Mulholland, Kim
    Pecenka, Clint
    Clark, Andrew
    VACCINE, 2023, 41 (46) : 6782 - 6790
  • [27] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB AS A PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK LATE PRETERM INFANTS IN THE NETHERLANDS
    Langenfeld, M. K.
    Visser, S.
    VALUE IN HEALTH, 2013, 16 (07) : A372 - A372
  • [28] Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan
    Shinichi Noto
    Alexia Kieffer
    Samira Soudani
    Takeshi Arashiro
    Chiho Tadera
    Sebastien Eymere
    Tobiasz Lemański
    Xinyu Wang
    Infectious Diseases and Therapy, 2025, 14 (4) : 847 - 865
  • [29] Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Solakidi, Argyro
    Markatis, Eleftherios
    Detsis, Marios
    Mendes, Diana
    Barmpouni, Myrto
    VACCINES, 2024, 12 (11)
  • [30] Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
    Averin, Ahuva
    Huebbe, Bennet
    Atwood, Mark
    Bayer, Lea J.
    Lade, Caroline
    von Eiff, Christof
    Sato, Reiko
    EXPERT REVIEW OF VACCINES, 2025, 24 (01) : 1 - 10
12345